166755-34-6

Upstream product

• 2393-23-9 4-methoxy-benzylamine 
• 1026883-56-6 6-Bromomethyl-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidine-5-carbaldehyde 
• 608-34-4 3-methyluracil 
• 58481-19-9 1-isobutyl-3-methylpyrimidine-2,4(1H,3H)-dione 
• 166754-96-7 5-cyano-3,6-dimethyl-1-(2-methylpropyl)pyrimidine-2,4-dione 
• 133181-39-2 5-cyano-6-methyl-1-(2-methylpropyl)pyrimidine-2,4-dione 
• 166755-03-9 3,6-dimethyl-5-formyl-1-(2-methylpropyl)pyrimidine-2,4-dione 
• 36980-62-8 [(2Z)-2-cyano-3-ethoxybut-2-enoyl]aminocarboxylic acid ethyl ester 

Downstream Products

• 1228688-20-7 5-chloro-1-isobutyl-6-(4-methoxybenzyl)-3-methyl-1H-pyrrolo[3,4-d]pyrimidine-2,4(3H,6H)-dione 

Relevant academic research and scientific papers

PDE1 inhibitor compounds

The present invention relates to optionally substituted (5- or 7-oxy)-3,4-dihydro-(optionally 4-oxo, 4-thioxo or 4-imino)-1H-pyrrolo[3,4-d]pyrimidin-2(3H,6H)-ones, e.g., Compounds of Formula II-A′ or II-B′ as described herein, processes for their producti

Novel Inhibitors of the Nuclear Factor of Activated T Cells (NFAT)-Mediated Transcription of β-Galactosidase: Potential Immunosupressive and Antiinflammatory Agents

The preparation of a series of quinazoline-2,4-diones, 1-3, and pyrrolopyrimidine-2,4-diones, 4-8 is described.A small number of quinazolinedione analogs were identified from random screening to possess low micromolar (1.3-4.4 μM) potency in the nu